{"id":"trimethoprim-sulfamethoxazole-metronidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Metallic taste (metronidazole)"},{"rate":null,"effect":"Rash (TMP-SMX)"},{"rate":null,"effect":"Photosensitivity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL443","moleculeType":"Small molecule","molecularWeight":"253.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trimethoprim-sulfamethoxazole (TMP-SMX) blocks sequential steps in bacterial folate metabolism, inhibiting dihydrofolate reductase and dihydropteroate synthase, thereby preventing nucleotide synthesis. Metronidazole is a nitroimidazole that generates reactive intermediates in anaerobic organisms, causing DNA strand breaks and cell death. Together, they provide synergistic coverage for mixed aerobic-anaerobic infections.","oneSentence":"This combination uses two antibiotics with different mechanisms—trimethoprim-sulfamethoxazole inhibits bacterial folate synthesis, while metronidazole disrupts DNA in anaerobic organisms—to provide broad-spectrum coverage against aerobic and anaerobic bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:33.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mixed aerobic-anaerobic bacterial infections"},{"name":"Intra-abdominal infections"},{"name":"Polymicrobial infections"}]},"trialDetails":[{"nctId":"NCT07451171","phase":"PHASE2","title":"Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Small Intestine Bacterial Overgrowth","enrollment":60},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30},{"nctId":"NCT02473796","phase":"NA","title":"Home Based Child Care to Reduce Mortality and Malnutrition in Tribal Children of Melghat, India: CRCT","status":"COMPLETED","sponsor":"MAHAN Trust","startDate":"2004-01","conditions":"Acute Respiratory Tract Infections, Diarrhea, Malaria","enrollment":7594},{"nctId":"NCT00613769","phase":"PHASE4","title":"Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery","status":"COMPLETED","sponsor":"Halmstad County Hospital","startDate":"2007-09","conditions":"Infection Prophylaxis in Colo Rectal Surgery","enrollment":1073},{"nctId":"NCT00355602","phase":"NA","title":"Antibiotics for the Treatment of Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-07","conditions":"Colitis, Ulcerative","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":249,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"trimethoprim-sulfamethoxazole + metronidazole","genericName":"trimethoprim-sulfamethoxazole + metronidazole","companyName":"Halmstad County Hospital","companyId":"halmstad-county-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses two antibiotics with different mechanisms—trimethoprim-sulfamethoxazole inhibits bacterial folate synthesis, while metronidazole disrupts DNA in anaerobic organisms—to provide broad-spectrum coverage against aerobic and anaerobic bacteria. Used for Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections, Polymicrobial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}